Clinical trials: Bladder Cancer Treatment
Overactive Bladder
Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
The purpose of this study is to determine whether Succinate of Solifenacin reduces the OverActive Bladder syndrome occurring during prostate irradiation.
- Trial name
- VesiCaP (NCT02805452)
- Testing
- Succinate of Solifenacin
- Where
- 5 sites in France
- Volunteers
- 4 people
- Sponsor
- Center Eugene Marquis
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00005958
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Sponsor
- Amgen
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network
High-risk Non-muscle Invasive Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the…
- Trial name
- NCT03711032
- Testing
- Pembrolizumab, BCG
- Where
- 209 sites in United States, Australia and 28 more
- Volunteers
- 1,397 people
- Sponsor
- Merck Sharp & Dohme LLC
Infiltrating Bladder Urothelial Carcinoma
Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer
This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder…
- Trial name
- NCT02688348
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Urinary Bladder Cancer
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
Patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant Carboplatin(AUC4)-Gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant…
- Trial name
- NCT05822934
- Testing
- Carboplatin-Gemcitabine Cisplatin-Gemcitabine
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Bladder Cancer, NMIBC
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
Bladder cancer is a common malignancy in the urinary system, ranking 11th in cancer incidence in China (3.48/100,000), with male incidence ranking 8th (5.70/100,000).
- Trial name
- NCT06735287
- Testing
- bladder sparing set, RC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gall Bladder Cancers
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
Locally advanced Gall bladders cancers not amenable for curative resection are often treated with chemotherapy alone which is the current standard of care.
- Trial name
- POLCAGB (NCT02867865)
- Testing
- Gemcitabine, Cisplatin, Chemoradiation
- Where
- India
- Volunteers
- 124 people
- Sponsor
- Tata Memorial Hospital
Interstitial Cystitis, Recurrent Cystitis
Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
This study aims to evaluate a catheter-free method for delivering medications directly into the bladder, known as intravesical instillation, which is commonly used to treat conditions such as interstitial cystitis/bladder pain…
- Conditions
- Interstitial Cystitis, Recurrent Cystitis, Haemorrhagic Cystitis, Bladder Cancer
- Trial name
- NOCATIN (NCT06719232)
- Testing
- Catheter-Free Intravesical Instillation with a special syringe adapter
- Where
- 2 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Jahn Ferenc South Pest Teaching Hospital
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors.
- Trial name
- NCT06129084
- Testing
- FGFR Testing
- Where
- 7 sites in Canada
- Volunteers
- 260 people
- Sponsor
- Bernie Eigl
Bladder Cancer
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI)…
- Trial name
- NCT01498172
- Testing
- MAGE-A3 ASCI, BCG
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Patrice Jichlinski
Bladder Cancer
Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making
The therapeutic approach to bladder cancer is strongly dependent on tumor stage and grade. Patients with non-muscle-invasive tumors (NMIBC) are usually treated with surgical resection of the tumor alone, whereas patients with…
- Trial name
- SBCT (NCT04533672)
- Testing
- MRI Sequences
- Where
- Switzerland
- Volunteers
- 186 people
- Sponsor
- University of Zurich
Prostate Cancer Patients Treated by Radiotherapy
Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer
The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes <200 ml during the…
- Trial name
- REFILL-PAC (NCT06653751)
- Testing
- Reminder App
- Where
- 5 sites in Denmark, Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Schleswig-Holstein
Urothelial Carcinoma
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma that has specific changes in…
- Trial name
- NCT02236195
- Testing
- Mocetinostat
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mirati Therapeutics Inc.
Bladder Cancer
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients…
- Trial name
- NCT00216814
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone.
- Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms
- Trial name
- NCT00315237
- Testing
- vinflunine and best supportive care
- Where
- 10 sites in Canada
- Volunteers
- 364 people
- Sponsor
- Pierre Fabre Medicament
Gall Bladder Cancer
Radiation Therapy in Unresectable Gall Bladder Cancer
The goal of this clinical trial is to compare two treatment regimes, namely, systemic therapy (chemotherapy and/or immunotherapy) alone vs.
- Trial name
- RUGB (NCT06214572)
- Testing
- Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin)
- Where
- India
- Volunteers
- 249 people
- Sponsor
- Tata Memorial Centre